Category: science translational medicine

“Game-changer” breast cancer study retracted as Indiana researcher out of his post

A group of cancer researchers whose work has been questioned by sleuths has been hit with their third retraction in less than a year.  

Today, Science Translational Medicine (STM) withdrew a 2021 breast cancer study by former Indiana University researcher Yujing Li and 12 other authors for image falsification. The immunotherapy study had been described by senior author Xiongbin Lu as a “game-changer” for triple negative breast cancer in a 2021 IU press release. 

The paper’s April 15 retraction notice states that a joint research misconduct investigation involving Indiana University, The Ohio State University, and the University of Maryland, College Park determined “falsification occurred during creation of figure S9C.” The institutions alerted the American Association for the Advancement of Science of the misconduct late last year and requested the paper’s retraction, according to Meagan Phelan, a spokesperson for AAAS, which publishes STM.

Continue reading “Game-changer” breast cancer study retracted as Indiana researcher out of his post

Indiana University paper about lung transplantation retracted after misconduct finding

After a finding of data manipulation, the corresponding author of a 2014 paper by a team of researchers at Indiana University has retracted the work.

Here’s the notice in Science Translational Medicine: Continue reading Indiana University paper about lung transplantation retracted after misconduct finding

“Data had been manipulated:” Science Translational Medicine retracts paper

Science Translational Medicine has retracted a paper by researchers based in Switzerland, after an investigation concluded two figures had been manipulated.

The investigation occurred at the University of Basel. It’s not clear what prompted it, but the paper has been discussed at length on PubPeer. After the investigation concluded two figure panels included manipulated data, the last author asked to retract the paper.

Here’s the notice:

Continue reading “Data had been manipulated:” Science Translational Medicine retracts paper

Widely used brain tumor cell line may not be what researchers thought it was

Bengt Westermark
Bengt Westermark

Nearly 50 years ago, researchers in Uppsala, Sweden used cells from a patient to establish a brain tumor cell line that has become widely used. But a new study suggests that the most common source of that cell line used by scientists today may not be derived from that original patient’s tumor, raising questions about the results obtained in hundreds of studies.

In a new paper out today in Science Translational Medicine, Bengt Westermark, of Uppsala University, and colleagues describe what they found when they performed a forensic DNA analysis comparing the widely used version of the cell line to the original. The findings are consistent with those of other analyses in which cell lines turn out not to be what researchers thought, a problem we’ve focused some attention on.

Here’s an email interview with Westermark about the findings and their implications: Continue reading Widely used brain tumor cell line may not be what researchers thought it was

What does “reproducibility” mean? New paper seeks to standardize the lexicon

Science Translational MedicineWhat is the difference between “reproducible” and “replicable”? And how does each relate to results that are “generalizable” and “robust”?

Researchers are using these terms interchangeably, creating confusion over what exactly is needed to confirm a scientific result, argues a new paper published today in Science Translational Medicine.

Here’s how the US National Science Foundation (NSF) defines “reproducibility,” according to the authors: Continue reading What does “reproducibility” mean? New paper seeks to standardize the lexicon

Downstream effects: Comment on retracted narcolepsy paper retracted

stmcoverThe recent retraction of a paper in Science Translational Medicine reporting “one of the biggest things to happen” in narcolepsy research has claimed a bystander: A letter that commented on the no-longer-landmark article.

The authors of the letter are with GlaxoSmithKline’s vaccine division. Here’s the new notice: Continue reading Downstream effects: Comment on retracted narcolepsy paper retracted

Authors retract paper “confirming” that narcolepsy is an autoimmune disease

stmA group of researchers at Stanford and elsewhere is retracting a 2013 paper that another scientist told Nature was “one of the biggest things to happen in the narcolepsy field for some time.”

The Science Translational Medicine paper caused a buzz because it claimed to show that narcolepsy was an autoimmune disease. Here’s the notice: Continue reading Authors retract paper “confirming” that narcolepsy is an autoimmune disease